<DOC>
	<DOCNO>NCT01578447</DOCNO>
	<brief_summary>The purpose study assess acceptability side effect low-dose injectable contraceptive formulation deliver skin ( subcutaneously ) , compare injectable contraception deliver muscle ( intramuscularly ) among adult HIV-positive woman attend mobile clinic HIV care wish use injectable contraception . The investigator also assess experience experience deliver two type injection among health care provider work within HIV care clinic .</brief_summary>
	<brief_title>Acceptability Depo-subQ Provera 104 Uniject vs. Intramuscular Depo-Provera Among HIV+ Women &amp; Providers , Uganda</brief_title>
	<detailed_description />
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<criteria>HIV+ Woman age 1845 Wishes prevent pregnancy use injectable contraception intend continue use injectable contraception next nine month Medically eligible injectable contraception Capable providing informed consent Willing provide contact information Agrees trial participation Intends live area next nine month May may currently use firstline antiretroviral therapy regimen ( include : AZT/3TC/EFV ; AZT/3TC/NVP ; CBV/EFV ; D4T/3TC/EFV ; D4T/3TC/NVP ; TDF/3TC/EFV ; TDF/3TC/NVP ) Currently pregnant Desires pregnancy within next nine month Contraindications use injectable contraception On secondline antiretroviral therapy regimen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>injectable contraception</keyword>
	<keyword>acceptability</keyword>
	<keyword>intramuscular</keyword>
	<keyword>subcutaneous</keyword>
</DOC>